This author has not written his bio yet.
But we are proud to say that Etira contributed 37 entries already.
Sydney, Australia – June 2, 2025: Etira, a clinical-stage biopharmaceutical company focused on developing cancer therapies, announced the activation of a new trial site at Macquarie University Hospital (MUH) in Sydney, New South Wales. The facility joins The Kinghorn Cancer Centre and Cancer Research South Australia as an active recruitment site for Etira’s ongoing ERX-315-001 […]
Chicago, IL – April 30, 2025: Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. Adriana Baker, who presented a poster titled “ERX-315 targets LIPA and potently causes catastrophic endoplasmic reticulum stress in multiple subtypes of hepatocellular […]
Chicago, IL – April 23, 2025: Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as a powerful breakthrough in ovarian cancer treatment, rigorously assess synergy of ERX-208 with FDA-approved drugs, and validate […]
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research South Australia (CRSA) located in Adelaide, South Australia. CRSA was activated after the site initiation visit to review study related protocol, procedures, […]
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase 1 trial (NCT06533332). ERX-315 is Etira’s first-in-class small molecule drug designed to induce endoplasmic reticulum stress leading to death of cancer […]
Dallas, TX – December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D., as its Chief Medical Officer (CMO). “We are excited that Dr. Raj will continue driving clinical efforts with our leadership team as […]
Sydney, Australia – November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia. ERX-315 is Etira’s first-in-class small molecule drug designed to selectively induce catastrophic endoplasmic reticulum stress in […]
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing new cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath, MD, PhD to its Board of Directors. The new board members bring a strong blend of clinical, technical, and commercial experience and expertise. […]
Seattle, WA – September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is targetable and the clinical utility of ERX-208.
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney Australia for the ERX-315-001 Phase 1 clinical trial. The study related protocol, procedures, processes, monitoring plan and study logistics […]
Dallas Office:
3033 Irving Blvd,
Dallas. TX. 75247
Mailing Address:
3060 Pegasus Park Dr.
Dallas. TX. 75247